IFNG — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29399207	0.49	2/20
SCHEMBL22360286	0.49	2/20
SCHEMBL19731887	0.48	2/20
1-Hexanol (SCHEMBL28255075)	0.47	2/20
SCHEMBL21179890	0.47	2/20
SCHEMBL24067596	0.46	2/20
Tetrabuthylammonium (SCHEMBL28243195)	0.46	2/20
SCHEMBL28257936	0.45	2/20
SCHEMBL18312441	0.45	2/20
SCHEMBL18313211	0.45	2/20
SCHEMBL21843053	0.45	2/20
Water (SCHEMBL28083873)	0.45	2/20
SCHEMBL28313706	0.45	2/20
Bromide (SCHEMBL28881717)	0.45	2/20
SCHEMBL29614646	0.45	2/20
SCHEMBL18312573	0.45	2/20
SCHEMBL18312865	0.45	2/20
Cetylpyridinium (SCHEMBL28131757)	0.45	2/20
SCHEMBL15616831	0.44	2/20
SCHEMBL18373332	0.44	2/20

Clinical trials — most relevant to IFNG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma	PHASE4	COMPLETED
Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis	PHASE3	COMPLETED
Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts	PHASE3	COMPLETED
Observation on the Efficacy and Mechanism of SLIT With Dust Mite Allergen for PAR	PHASE2/PHASE3	UNKNOWN
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients	PHASE2	UNKNOWN
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer	PHASE2	UNKNOWN
Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma	PHASE2	COMPLETED
ACTIMMUNE in Intermediate Osteopetrosis	PHASE2	COMPLETED
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs	PHASE2	COMPLETED
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis	PHASE2	COMPLETED
Mechanistic Study of Indigo Naturalis in Treating Psoriasis	PHASE2	COMPLETED
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma	PHASE2	COMPLETED
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease	PHASE2	COMPLETED
Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis	PHASE2	COMPLETED
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer	PHASE2	WITHDRAWN
Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors	PHASE1	COMPLETED
Effect of IFN-γ on Innate Immune Cells	PHASE1	COMPLETED
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation	EARLY_PHASE1	COMPLETED
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts	nan	COMPLETED
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma	nan	COMPLETED
Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals	nan	UNKNOWN
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis	nan	UNKNOWN
Kinetics of INF-γ Production in Intensive Care Patients	nan	RECRUITING
Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions	nan	UNKNOWN
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts	nan	COMPLETED
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being	nan	UNKNOWN
TGF β 1 Expression Related Gene Polymorphism	nan	RECRUITING
Long COVID Ultrasound Trial	nan	COMPLETED
Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IFNG binder may also engage these)

Protein	Name	Similarity
P42162	—	1.000	P42162 →
P63311	—	1.000	P63311 →
P63309	—	1.000	P63309 →
Q5I6S9	—	0.999	Q5I6S9 →
Q9TTB0	—	0.998	Q9TTB0 →
P79154	—	0.998	P79154 →
P63310	—	0.998	P63310 →
Q866Y6	—	0.996	Q866Y6 →
Q865Y4	—	0.996	Q865Y4 →
Q8MKF5	—	0.994	Q8MKF5 →
Q10420	—	0.994	Q10420 →
P28341	—	0.994	P28341 →
P07353	—	0.994	P07353 →
P28333	—	0.994	P28333 →
P34566	—	0.993	P34566 →
Q865W6	—	0.993	Q865W6 →
B9UJ97	—	0.993	B9UJ97 →
P01581	—	0.993	P01581 →
Q25BC0	—	0.993	Q25BC0 →
P42161	—	0.993	P42161 →
Q1ECV8	—	0.993	Q1ECV8 →
P17773	—	0.993	P17773 →
Q8SPW9	—	0.993	Q8SPW9 →
Q4ZH68	—	0.992	Q4ZH68 →
P22047	—	0.992	P22047 →
Q9KPU8	—	0.992	Q9KPU8 →
P01580	—	0.992	P01580 →
Q9CY02	—	0.992	Q9CY02 →
Q2PE75	—	0.992	Q2PE75 →
Q77GW1	—	0.992	Q77GW1 →